COVID-19 AND PATIENTS UNDERGOING PHARMACOLOGICAL TREATMENTS FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES: PROTOCOL FOR A RAPID LIVING SYSTEMATIC REVIEW

Maria Eduarda dos Santos Puga; Aline Pereira da Rocha; Alvaro Nagib Atallah; Ana Carolina Pereira Nunes Pinto; César Ramos Rocha-Filho; Felipe Sebastião de Assis Reis; Keilla Martins Milby; Vinicius Tassoni Civile; Nelson Carvas Junior; Rodolfo Rodrigo Pereira Santos; Laura Jantsch Ferla; Giulia Fernandes Moça Trevisani; Gabriel Sodré Ramalho; Maria Eduarda dos Santos Puga; Virgínia Fernandes Moça Trevisani

doi:10.1590/SciELOPreprints.349

article.authors6a09588ccfbfe

Maria Eduarda dos Santos Puga Universidade Federal de São Paulo. Centro Cochrane do Brasil https://orcid.org/0000-0001-8470-861X
Aline Pereira da Rocha MSc, Pharmacist, PhD Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP) and Volunteer Researcher, Cochrane Brazil, São Paulo (SP), Brazil https://orcid.org/0000-0002-0863-6500
Alvaro Nagib Atallah MD, MSc, PhD. Nephrologist and Full Professor, Discipline of Emergency and Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), and Director, Cochrane Brazil, São Paulo (SP), Brazil.
Ana Carolina Pereira Nunes Pinto MSc, Physiotherapist, PhD Student., Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP); Professor, Biological and Health Sciences Department, Universidade Federal do Amapá (AP), Brazil and Volunteer Researcher, Cochrane Brazil, São Paulo (SP), Brazil https://orcid.org/0000-0002-1505-877X
César Ramos Rocha-Filho MSc, Biotechnologist, PhD Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP). https://orcid.org/0000-0002-7190-0263
Felipe Sebastião de Assis Reis MD, MPS, Technologies and Healthcare. Manager, Medical Practices, Beneficência Portuguesa de São Paulo. https://orcid.org/0000-0002-5728-4863
Keilla Martins Milby Nurse, PhD Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP) and Volunteer Researcher, Cochrane Brazil, São Paulo (SP), Brazil https://orcid.org/0000-0003-0601-457X
Vinicius Tassoni Civile MSc, Physiotherapist, PhD Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP); Assistant Professor, Physiotherapy Course, Paulista University and Volunteer Researcher, Cochrane Brazil, São Paulo (SP), Brazil. https://orcid.org/0000-0002-1718-6281
Nelson Carvas Junior Physical Educator. Ibirapuera University https://orcid.org/0000-0003-2168-8927
Rodolfo Rodrigo Pereira Santos Statistician. MSc Student, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP). Data Science Manager, Synova Health CRO https://orcid.org/0000-0003-1540-7586
Laura Jantsch Ferla Undergratuate Medical Student, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (Unifesp), São Paulo (SP), Brazil https://orcid.org/0000-0002-8162-2068
Giulia Fernandes Moça Trevisani Undergraduate Medical Student at Universidade Santo Amaro, São Paulo (SP), Brazil https://orcid.org/0000-0003-3581-3047
Gabriel Sodré Ramalho Undergratuate Medical Student, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (Unifesp), São Paulo (SP), Brazil. https://orcid.org/0000-0001-7201-2308
Maria Eduarda dos Santos Puga Librarian, Evidence-Based Health Program, Universidade Federal de São Paulo (UNIFESP). Information Specialist Brazilian Cochrane Centre
Virgínia Fernandes Moça Trevisani MD, MSc, PhD Rheumatologist. Discipline of Emergency and Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo (SP), Brazil

DOI:

https://doi.org/10.1590/SciELOPreprints.349

Keywords:

Immune-mediated diseases, living systematic review, COVID-19

Resumen

CONTEXT AND OBJECTIVE: We propose to systematically review the available evidence to evaluate if patients with immune mediated or inflammatory diseases under pharmacological treatment with immunosuppressants, immunobiologics, DMARDs or targeted synthetic DMARDs have better or worse outcomes when infected by SARS-CoV-2. This study is a protocol for our rapid living systematic review. METHODS: Protocol for a rapid living systematic review methodology following the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidance. To conduct the rapid systematic review, we will employ abbreviated systematic review methods, including: not performing independent screens of abstracts and not searching grey literature. As this will be a living review, it will be continuously updated.